Firefly Neuroscience Reports 72% Revenue Growth in Q2 2026, Faces Operating Loss

Firefly Neuroscience, Inc. reported significant financial developments in its latest 10-Q filing for the second quarter of 2026, revealing a revenue increase of 72% year-over-year. The company generated $514,000 in revenue for the three months ended June 30, 2026, compared to $299,000 for the same period in 2025. For the six months ended June 30, 2026, revenue reached $999,000, a substantial rise from $342,000 in the prior year. This growth is primarily attributed to the acquisition of Evoke Neuroscience, which has expanded Firefly's product offerings and customer base.

Despite the revenue growth, Firefly reported an operating loss of $1.974 million for the second quarter, compared to a loss of $1.634 million in the same quarter of 2025. The total operating expenses increased to $2.227 million from $1.908 million, driven by higher research and development costs, which rose to $525,000 from $336,000. General and administrative expenses also increased, reflecting higher bonus expenses. The net loss for the second quarter was $1.984 million, slightly higher than the $1.833 million loss reported in the same quarter last year.

In terms of operational metrics, Firefly's cash position improved significantly, with cash and cash equivalents totaling $9.226 million as of June 30, 2026, up from $2.747 million at the end of 2025. The company raised $10.277 million in gross proceeds through private placements and warrant exercises during the first half of 2026. However, Firefly continues to face challenges, including an accumulated deficit of $115.558 million and negative cash flow from operations of $3.698 million for the six months ended June 30, 2026.

Strategically, Firefly has been focusing on expanding its market presence and product adoption. The company operates the Evoke EEG System, which is currently in use at over 85 clinical sites across the United States. This system is designed to enhance clinical decision-making through advanced neurophysiological assessments. Firefly's business model is subscription-based, which allows for recurring revenue as clinicians increasingly integrate electrophysiological assessments into their practices.

Looking ahead, Firefly's management has expressed concerns regarding its ability to continue as a going concern, citing the need for substantial additional capital to fund ongoing operations and achieve profitability. The company plans to manage its operating expenses carefully and leverage synergies from the Evoke acquisition to drive revenue growth. However, the success of these strategies is contingent on market conditions and the company's ability to secure further financing.